AORT — Artivion, Inc.

Summary of AORT Q3 2025 Earnings Call

1. Key Financial Results and Metrics:

• Total Revenues: $113.4 million, up 16% year-over-year on a constant currency basis.
• Adjusted EBITDA: Increased 39% to $24.6 million, with an adjusted EBITDA margin of 21.7%, a 320 basis point improvement from the previous year.
• Gross Margin: Improved to 65.6% from 63.7% year-over-year.
• Free Cash Flow: $17.7 million for Q3; expected to be slightly cash flow negative for the full year due to a one-time cash payment related to facility purchases.
• Debt: $214.9 million, with a net leverage ratio reduced to 1.8 from 3.9 a year ago.

2. Strategic Updates and Business Highlights:

• Product Growth:
  • Stent graft revenues grew 31%, driven by the AMDS launch.
  • On-X valve revenues increased 23%, supported by market share gains and positive clinical data.
• AMDS Launch: Positive early adoption and feedback, with a new reimbursement code (DRG-209) enhancing the economic value proposition.
• Facility Expansion: Acquired two facilities in Austin, Texas, to support On-X manufacturing operations.
• Pipeline Progress:
  • First patient enrolled in the Arcevo LSA pivotal trial.
  • Continued focus on securing PMA for AMDS, with three of four modules filed for FDA approval expected in mid-2026.

3. Forward Guidance and Outlook:

• 2025 Revenue Guidance: Raised to $439 million to $445 million, reflecting constant currency growth of 13% to 14%.
• Adjusted EBITDA Guidance: Expected to be between $88 million and $91 million, representing 24% to 28% growth over 2024.
• 2026 Outlook: Anticipates continued double-digit revenue growth, though tougher comparisons expected for AMDS due to prior year contributions.

4. Bad News, Challenges, or Points of Concern:

• Tougher Comparisons for AMDS: As AMDS revenue grows, comparisons to prior year performance will become more challenging.
• Tissue Processing Revenue: Expected to be relatively flat for 2025, with mid-single-digit growth anticipated for 2026 and beyond.
• Cybersecurity Incident Costs: Ongoing costs from the 2024 cybersecurity incident continue to impact financials, with insurance reimbursement processes expected to take time.

5. Notable Q&A Insights:

• AMDS Performance: Revenue is currently driven by initial stocking rather than implantations, but early adoption feedback is positive.
• On-X Growth Drivers: Growth attributed to both market share gains and new clinical data supporting mechanical valves, particularly in younger patients.
• NEXUS Approval: The decision to exercise the option for acquiring Endospan will depend on upcoming clinical data expected in January 2026.
• Arcevo Market Size: Estimated at $80 million in the U.S., with recruitment for the trial expected to progress over the next 12 to 18 months.

Overall, Artivion demonstrated strong financial performance in Q3 2025, driven by significant growth in its stent graft and On-X product lines, while also navigating challenges related to AMDS comparisons and cybersecurity incident costs. The company remains optimistic about its growth trajectory and pipeline advancements.